Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

446 results found

Commentary
Ask Lexy

Smart & Biggar | Canada | 26 Jan 2022

Certificate of supplementary protection filing fee increase effective 1 April 2022

On 1 April 2022, the fee for filing a certificate of supplementary protection will increase from C$9,756 to C$9,952 in accordance with subsection 9(1) of the Certificate of Supplementary Protection Regulations.
Commentary
Ask Lexy

Grau & Angulo | Spain | 24 Jan 2022

Madrid Court of Appeal confirms dismissal of infringement action in bosentan patent case

The Madrid Court of Appeal recently dismissed an appeal filed by Actelion Pharmaceuticals Limited and Actelion Pharmaceuticals España in a patent infringement case regarding the drug bosentan (Tracleer). In doing so, the Court confirmed that, once granted with process claims only for Spain, the protection conferred by a European patent cannot be subsequently extended by adding product or use......
Commentary
Ask Lexy

Smart & Biggar | Canada | 17 Nov 2021

Federal Court remits Belsomra CSP timing refusal for redetermination

In August 2019, the minister of health denied Merck's application for a certificate of supplementary protection (CSP) for Canadian Patent No. 2,670,892 relating to the drug suvorexant (Merck's Belsomra). The Federal Court recently set aside the minister's decision and remitted Merck's CSP application for redetermination. This decision adds to the Court's growing CSP jurisprudence.
Commentary
Ask Lexy

Pearl Cohen Zedek Latzer Baratz | Israel | 25 Oct 2021

Loophole to enhance generics' ability to launch at risk during patent term extension protection period

The Israeli Ministry of Justice has proposed changes to Israel's patent term extension laws that significantly enhance generics' ability to launch at risk. Although the proposal ostensibly offers Israeli generics the same benefits afforded to European generics, the proposal does not include the safeguards found in the European regulations. If the proposal is ratified, innovators will need to......
Article
Ask Lexy

William Fry | Ireland | 22 Oct 2021

Ireland Launches Intellectual Property and Technology Court and Reforms IP Disputes Procedures

A new division of Ireland's Commercial Court dedicated to intellectual property cases and disputes about complex technology has been established…
Article
Ask Lexy

Bird & Bird LLP | European Union, Italy | 5 Oct 2021

Year in review: notable 2020 Patent Cases in Italy

The Supreme Court held that prosecution history estoppel has no legal basis in the Italian patent law system. The assessment of patent infringement…
Article
Ask Lexy

Bird & Bird LLP | European Union, Spain | 5 Oct 2021

Year in review: notable 2020 Patent Cases in Spain

Ferring International appealed the decision to the High Court of Justice of Madrid against the decision of the Spanish Patent and Trademark Office…
Commentary
Ask Lexy

Grau & Angulo | Spain | 12 Jul 2021

Ezetimibe and simvastatin combination SPC revoked by Barcelona Patent Court

The Barcelona Commercial Court Number 5 recently declared the Spanish supplementary protection certificate (SPC) covering the combination of ezetimibe and simvastatin to be invalid. The case was deliberated by the three Barcelona patent judges, who upheld the defendants' arguments and declared SPC'011 for ezetimibe and simvastatin invalid, dismissing MSD's infringement action.
Article
Ask Lexy

Bereskin & Parr LLP | Canada | 7 Jul 2021

2021 Canadian Pharma Litigation Mid-Year Recap: Key Takeaways from the Year So Far

Despite continued COVID-19 lockdowns and restrictions, 2021 has seen no shortage of Canadian judicial and patent Appeal Board decisions affecting the…
Article
Ask Lexy

Haley Guiliano LLP | European Union, United Kingdom | 25 Mar 2021

The Post-Brexit IP Landscape: SPCs

Supplementary protection certificates (SPCs) allow for up to five and half years of additional patent protection for a medicinal product that has been…
Previous page 1 2 3 ...